Longboard Pharmaceuticals has commenced the international Phase III DEEp SEA Study of its investigational asset bexicaserin ...

David Sallman, MD, discusses some of the innovative therapies and strategies being investigated in myelodysplastic syndromes studies.

The biotech sector was in focus last week, with regular pipeline and regulatory updates. Drug approvals were in the spotlight ...

Shares of Celldex Therapeutics CLDX lost 12.1% on Wednesday due to unsatisfactory 52-week safety data from a mid-stage study ...

Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of ...

Longboard Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it has initiated its ...

The Motiva implants feature the patented SmoothSilk surface, engineered to improve biocompatibility and minimise inflammation ...

Biomea Fusion Inc. (BMEA) announced that the U.S. Food and Drug Administration has lifted the clinical hold on the company's ongoing ...

A new lawsuit filed against Oregon Health & Science University sheds light on the risks of drug trials, with an OHSU employee ...

An international placebo-controlled study led by Cedars-Sinai suggests that a targeted drug therapy that was developed by ...